iPSC Derived CAR-Ts: Targeting Cancer with an Engineered, iPSC-Derived T Cell

Dr. Sadelain presented an overview of chimeric antigen receptor (CAR) and T cell receptor-modified T cell therapeutic strategies, including a history on the evolution of CAR-based strategies over the past two decades. He highlighted the clinical promise of this therapeutic approach, reviewed the challenges and limitations of current autologous approaches, and described the therapeutic advantages and potential strategies for generating “off-the-shelf” iPSC-derived T-cell therapies.